Search
With notable cases of pancreatic cancer in the news this year, MSK held an Information Session for Patients and Caregivers with the goal of helping people understand the disease and sharing some of the encouraging breakthroughs in research and treatment.
Memorial Sloan Kettering Cancer Center (MSK) has welcomed Whitney Snider, MD, MBA, as the inaugural Managing Partner of MSK Ventures – a dedicated investment pool that will raise and direct funds to high-growth, early-stage startups created and/or nurtured by MSK faculty and staff.
Learn about new findings regarding how inherited and acquired genetic mutations cause breast cancer resistance to certain therapies.
Two pivotal studies published in the New England Journal of Medicine and conducted by Memorial Sloan Kettering researchers offer proof of better treatment options for patients with advanced renal cell carcinoma (RCC), the most common form of kidney cancer.
Catch up with some of the patients we got to know in 2017.
At Memorial Sloan Kettering Cancer Center, more than half of patients with gallbladder cancer are diagnosed incidentally following elective cholecystectomy for assumed benign disease. The traditional treatment approach for these patients is re-resection to achieve a cure.
The multicenter project, which yielded dozens of scientific papers on more than 30 different kinds of cancer, has officially drawn to a close.
Experts from Memorial Sloan Kettering presented some of the latest research on this challenging complication of many cancer surgeries.
A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research.